Ann: Cynata secures commitments for $8.1m institutional placement, page-19

Yeah sure, it could.

I think the credit raise at a 20% discount to the closing price, coupled with positive readout of our second ever trial is a slap in the face.

In saying that, we now have money in the bank to last us through next 12 months.

I'm expecting MSB, if FDA accepted, will bring much needed exposure to the sector ( no pun intended).

Less then 18 months until the results of the large phase 3 trial results in osteoarthritis.
Which will.be a company maker, but even in the months leading up to that date, bets will be placed and a $1 share price next year is realistic.

But for now, all eyes on the blaster.